etoposide has been researched along with nutlin-3a in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 10 (62.50) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Garg, N; Gullberg, H; Gustavsson, AL; Haraldsson, M; Johansson, L; Ladds, MJGW; Lain, S; Lane, D; Larsson, J; Popova, G; Qian, W; Sahlberg, SH; Saleh, A; Sandberg, L; Yngve, U | 1 |
| Carvajal, D; Heimbrook, DC; Thompson, T; Tovar, C; Vassilev, LT; Vu, BT; Wahl, GM; Xu, Q; Yang, H | 1 |
| Chang, NS; Doherty, J; Ensign, A; Hong, Q; Hsu, LJ; Schultz, L | 1 |
| Austen, B; Best, OG; Dyer, MJ; Gardiner, AC; Ibbotson, R; Majid, A; Oscier, DG; Skowronska, A; Stankovic, T; Walewska, R | 1 |
| Arva, NC; Bargonetti, J; Brekman, A; Okoro, DR; Qiu, WG; Talbott, KE | 1 |
| Garibal, J; Hollville, E; Pujals, A; Renouf, B; Tétaud, C; Wiels, J | 1 |
| Cho, BJ; Hong, SW; Hwang, YI; Jin, DH; Jung, DJ; Kang, JS; Kim, D; Kim, JE; Lee, WJ; Shin, JS | 1 |
| Bartel, F; Blaydes, JP; Böhnke, A; Darley, M; de Lange, J; Emaduddin, M; Jochemsen, AG; Lam, S; Lenos, K; Lodder, K; Phillips, A; Richter, J; Teunisse, A; Verlaan-de Vries, M; Wolf, A | 1 |
| Wesierska-Gadek, J | 1 |
| Blagosklonny, MV; Leontieva, OV | 1 |
| Cavallini, S; Mariani, L; Rainaldi, G; Rizzo, M; Simili, M | 1 |
| Blagosklonny, MV; Burdelya, LG; Demidenko, ZN; Gudkov, AV; Leontieva, OV; Natarajan, V | 1 |
| Algül, H; Conradt, L; Henrich, A; Krämer, OH; Lesina, M; Reichert, M; Saur, D; Schmid, RM; Schneider, G; Wirth, M | 1 |
| Cox, M; Loughery, J; Meek, DW; Smith, LM | 1 |
| Carrillo, AM; Eischen, CM; Hicks, M; Khabele, D | 1 |
| Alexander, KA; Berger, SL; Catizone, AN; Good, CR; Sammons, MA | 1 |
16 other study(ies) available for etoposide and nutlin-3a
| Article | Year |
|---|---|
Optimization of Tetrahydroindazoles as Inhibitors of Human Dihydroorotate Dehydrogenase and Evaluation of Their Activity and In Vitro Metabolic Stability.
Topics: Animals; Cell Survival; Dihydroorotate Dehydrogenase; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Female; Humans; Indazoles; Mice; Microsomes, Liver; Oxidoreductases Acting on CH-CH Group Donors | 2020 |
Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis.
Topics: Annexin A5; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Line, Tumor; Coloring Agents; DNA; Dose-Response Relationship, Drug; Doxorubicin; Enzyme-Linked Immunosorbent Assay; Etoposide; Humans; Imidazoles; Kinetics; Nuclear Proteins; Phosphorylation; Piperazines; Polymerase Chain Reaction; Protein Binding; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Serine; Transcriptional Activation; Tumor Suppressor Protein p53 | 2004 |
WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53.
Topics: Active Transport, Cell Nucleus; Animals; Anisomycin; Cell Line, Tumor; Cell Nucleus; Cytoplasm; Cytosol; DNA, Complementary; Dose-Response Relationship, Drug; Etoposide; Fibroblasts; Genes, Dominant; Humans; Hypoxia; Imidazoles; Immunoprecipitation; Luminescent Proteins; Mice; Microscopy, Fluorescence; Models, Biological; Oxidoreductases; Phosphorylation; Piperazines; Proteasome Endopeptidase Complex; Protein Binding; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Serine; Staurosporine; Time Factors; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Two-Hybrid System Techniques; Tyrosine; U937 Cells; Ultraviolet Rays; WW Domain-Containing Oxidoreductase | 2005 |
A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p21; DNA-Binding Proteins; Etoposide; Genes, p53; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Piperazines; Protein Serine-Threonine Kinases; Tumor Suppressor Proteins | 2008 |
Disruption of the p53-Mdm2 complex by Nutlin-3 reveals different cancer cell phenotypes.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cloning, Molecular; DNA Damage; Etoposide; Flow Cytometry; Genotype; Humans; Imidazoles; Neoplasms; Phenotype; Piperazines; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-mdm2; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Protein p53 | 2008 |
Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells.
Topics: Apoptosis; Burkitt Lymphoma; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Etoposide; Herpesvirus 4, Human; Humans; Imidazoles; Piperazines; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-mdm2; Tumor Suppressor Protein p53 | 2009 |
Foxp3 expression in p53-dependent DNA damage responses.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Death; Cell Division; Colonic Neoplasms; DNA Damage; Doxorubicin; Etoposide; Female; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Imidazoles; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-mdm2; Tumor Suppressor Protein p53 | 2010 |
HDMX-L is expressed from a functional p53-responsive promoter in the first intron of the HDMX gene and participates in an autoregulatory feedback loop to control p53 activity.
Topics: Animals; Binding Sites; Blotting, Western; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Chromatin Immunoprecipitation; Doxycycline; Etoposide; Evolution, Molecular; Humans; Imidazoles; Introns; Mice; Nuclear Proteins; Piperazines; Promoter Regions, Genetic; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcription, Genetic; Tumor Suppressor Protein p53; Ubiquitination | 2010 |
mTOR and its link to the picture of Dorian Gray - re-activation of mTOR promotes aging.
Topics: Animals; Cell Cycle; Cell Proliferation; Cell Shape; Cellular Senescence; DNA Damage; Doxorubicin; Enzyme Activation; Etoposide; Humans; Imidazoles; Piperazines; Protein Kinase Inhibitors; Serum; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53; Up-Regulation | 2010 |
DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence.
Topics: Cell Cycle; Cell Line; Cell Proliferation; Cell Shape; Cellular Senescence; DNA Damage; Doxorubicin; Enzyme Activation; Etoposide; Humans; Imidazoles; Neoplasms; Piperazines; Protein Kinase Inhibitors; Retinal Pigment Epithelium; Serum; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53; Up-Regulation | 2010 |
The over-expression of miR-34a fails to block DoHH2 lymphoma cell proliferation by reducing p53 via c-MYC down-regulation.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Phytogenic; Base Sequence; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Down-Regulation; Etoposide; Gene Expression; Green Fluorescent Proteins; Humans; Imidazoles; Lymphoma; MicroRNAs; Piperazines; Proto-Oncogene Proteins c-bcl-6; Proto-Oncogene Proteins c-myc; RNA Interference; Transfection; Tumor Suppressor Protein p53 | 2012 |
Hypoxia suppresses conversion from proliferative arrest to cellular senescence.
Topics: Cell Hypoxia; Cell Line; Cell Proliferation; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Epithelial Cells; Etoposide; Fibroblasts; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imidazoles; Piperazines; Tumor Suppressor Protein p53 | 2012 |
Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death.
Topics: Amino Acid Chloromethyl Ketones; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; DNA Damage; Doxorubicin; Drug Synergism; Etoposide; Gemcitabine; Imidazoles; Immunohistochemistry; Immunoprecipitation; Indoles; Mice; Pancreatic Neoplasms; Piperazines; Proto-Oncogene Proteins c-mdm2; Pyrrolidinones; Topoisomerase II Inhibitors | 2013 |
Critical role for p53-serine 15 phosphorylation in stimulating transactivation at p53-responsive promoters.
Topics: Cell Line, Tumor; Chromatin; DNA Damage; Etoposide; Humans; Imidazoles; Mutation; Phosphorylation; Piperazines; Promoter Regions, Genetic; Serine; Transcriptional Activation; Tumor Suppressor Protein p53 | 2014 |
Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Comet Assay; DNA Breaks, Double-Stranded; DNA Damage; DNA Repair; Etoposide; Female; Fibroblasts; HEK293 Cells; Humans; Imidazoles; Mice; Mice, Transgenic; Mutagens; Ovarian Neoplasms; Piperazines; Proto-Oncogene Proteins c-mdm2; Tumor Suppressor Protein p53 | 2015 |
Comparison of genotoxic versus nongenotoxic stabilization of p53 provides insight into parallel stress-responsive transcriptional networks.
Topics: Apoptosis; Cell Line; Chromatin Assembly and Disassembly; DNA Damage; Etoposide; Fibroblasts; Gene Expression Regulation; Gene Regulatory Networks; Humans; Imidazoles; NF-kappa B; Nitriles; Piperazines; Protein Binding; Protein Stability; Proto-Oncogene Proteins c-mdm2; Sulfones; Transcriptional Activation; Tumor Suppressor Protein p53 | 2019 |